

NEONATAL

VECURONIUM

WARNING: Paralysing Agent

This document should be read in conjunction with this **DISCLAIMER**

Highly Restricted: Requires Neonatologist approval before commencing

A HIGH RISK Medication

Inadvertent use in patients without the availability of medical staff skilled in airway support can lead to respiratory arrest, permanent harm, or death.

Presentation	Vial: 10mg powder for reconstitution				
Classification	Non-depolarising neuromuscular blocking agent producing skeletal muscle paralysis. Causes less tachycardia and hypotension than pancuronium.				
Indication	Skeletal muscle relaxation or paralysis in mechanically ventilated infants and infants that are difficult to ventilate				
	 Moderately-severe to severe respiratory distress requiring increased ventilator settings 				
Dose	Difficulty ventilating/ Respiratory distress				
	IV:				
	Intermittent dosing: 30 -150 microgram /kg /dose				
	Usual dose: 100 microgram/kg				
	Dose may be repeated at intervals of 1 to 2 hours as needed for paralysis.				
	Continuous IV infusion:				
	Infusion rate: 1 – 1.5 microgram/kg/minute				
Monitoring	Monitor vital signs frequently, blood pressure continuously.				
Compatible Fluids	Glucose 5%, Sodium chloride 0.9%				

Proparation	<u>IV:</u>				
Preparation	Reconstitute the 10mg vial with 10mL of Water for Injections				
	Concentration is $10 \text{ mg}/10 \text{ mL} = 1 \text{ mg/mL}$				
	IV Infusion: Available from CIVAS (KEMH & PCH)				
	If unavailable prepare as follows:				
	Step 1: Reconstitution				
	Reconstitute the 10mg vial with 10mL of Water for Injections				
	Concentration is 10mg/10mL = 1mg/mL				
	Step 2: Dilution				
	Withdraw 6mg of vecuronium per kg of baby's weight (6mL/kg) and dilute to 50mL with appropriate infusion fluid.				
	This will give the following infusion rates:				
	 0.5 mL/hour = 1 microgram / kg / min 				
	 1 mL/hour = 2 microgram / kg / min 				
	 2 mL/hour = 4 microgram / kg / min 				
	•				
	If a different concentration is required, refer to <u>Calculation of the</u> <u>Composition of Medication Infusions</u>				
Administration	IV: Over 5-10 seconds				
	Onset of action: 1-2 minutes				
	Continuous infusion - as per prescribed infusion rate				
Adverse Reactions	Common:, heart rate and blood pressure may decrease when used with opioids				
	Serious: masking of convulsions				
Storage	Store at room temperature, below 25°C				
Interactions Aminoglycosides; general anaesthetics, corticosteroids: pote neuromuscular blockade:					
	Adrenaline: antagonism of neuromuscular blockade:.				
Notes	 Protect from light. Discard reconstituted vial immediately after use Use in conjunction with lubricating eye drops during paralysis Antidote: Neostigmine (See protocol) 				

References	Truven Health Analytics. Vecuronium. In: NeoFax [Internet]. Greenwork Village (CO): Truven Health Analytics; 2019 [cited 2019 Sep 3]. Availa from: <u>https://neofax.micromedexsolutions.com/</u>			
	Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2401. 2,p2021-2023.			
	Society of Hospital Pharmacists of Australia. Vecuronium. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 Sep 3]. Available from: <u>http://aidh.hcn.com.au</u>			

Document owner:	Head of Department - Neonatology				
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate				
Date first issued:	October 2008	Version:	4.0		
Last reviewed:	September 2019	Next review date:	September 2022		
Endorsed by:	Neonatal Directorate Management Group	Date:	September 2019		
Standards Applicable:	NSQHS Standards: 1				
Printed or personally saved electronic copies of this document are considered uncontrolled.					
Access the current version from the WNHS website.					

© Department of Health Western Australia 2019